Multiple ‘Centers of Excellence’ At FDA Could Create Review Inefficiencies – Jenkins

In an interview, US FDA’s outgoing head of new drug review cautions against duplicating the agency's Oncology Center of Excellence model across multiple therapeutic areas, advocating for a more "balanced portfolio" in structuring review operations.